http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017266168-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82a308524dd92f08d281d392c66fe6f7
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551
filingDate 2015-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2d71aa90da2dd9e3d6900ff85e02379
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05241ba08a5279a3ce9f117974a48eee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_129b118b8f42e739768afa07e59fd719
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ee47816aba29cd282135ce1ab84b332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be05aed48f567c14ec3faf3a120a53f8
publicationDate 2017-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2017266168-A1
titleOfInvention Methods for preventing or treating osteoarthritis
abstract One aspect of the invention provides a method for treating or preventing the development of osteoarthritis by administering to a subject in need of such treatment a composition including a therapeutically effective amount of an anti-fibrotic agent. In various embodiments, the anti-fibrotic agent is 5-methyl-1-phenylpyridin-2-one, tranilast, gamma-glutamyl transpeptidase inhibitor, fasudil, CC-930, T-5524, rosiglitazone, tocilizumab, E5564, TAK-242, GKT136901 or bosentan.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023184961-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019093166-A1
priorityDate 2014-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013166156-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7816383-B1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2345
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID77999
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396258
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393293
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051774
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395300
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395317
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104865
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396621
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID91670
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3547
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396964
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID244
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5282230
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416840
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID40632
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396651
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177

Total number of triples: 52.